BRPI0908569B8 - estimuladores de secreção de insulina derivados de piridopirazinonas, seu uso, e composição farmacêutica - Google Patents

estimuladores de secreção de insulina derivados de piridopirazinonas, seu uso, e composição farmacêutica

Info

Publication number
BRPI0908569B8
BRPI0908569B8 BRPI0908569A BRPI0908569A BRPI0908569B8 BR PI0908569 B8 BRPI0908569 B8 BR PI0908569B8 BR PI0908569 A BRPI0908569 A BR PI0908569A BR PI0908569 A BRPI0908569 A BR PI0908569A BR PI0908569 B8 BRPI0908569 B8 BR PI0908569B8
Authority
BR
Brazil
Prior art keywords
insulin secretion
pyridopyrazinones
pharmaceutical composition
derived insulin
secretion stimulators
Prior art date
Application number
BRPI0908569A
Other languages
English (en)
Inventor
Charon Christine
Valeur Eric
Botton Gérard
Kergoat Micheline
Elbawab Samer
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0908569A2 publication Critical patent/BRPI0908569A2/pt
Publication of BRPI0908569B1 publication Critical patent/BRPI0908569B1/pt
Publication of BRPI0908569B8 publication Critical patent/BRPI0908569B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

estimuladores de secreção de insulina derivados de piridopirazinonas, métodos para obtê-los e uso dos mesmos para o tratamento de diabetes. a presente invenção refere-se aos derivados piridopirazinona da fórmula (i), em que x, y, z, w, a e r1 são como definido na reivindicação 1, como estimuladores da secreção de insulina. a invenção também refere-se à preparação e uso desdes derivados de piridopirazinona para a profilaxia e/ou tratamento de diabetes e patologias associadas.
BRPI0908569A 2008-03-05 2009-02-27 estimuladores de secreção de insulina derivados de piridopirazinonas, seu uso, e composição farmacêutica BRPI0908569B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08004052 2008-03-05
EP08004052.0 2008-03-05
PCT/EP2009/001428 WO2009109341A1 (en) 2008-03-05 2009-02-27 Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Publications (3)

Publication Number Publication Date
BRPI0908569A2 BRPI0908569A2 (pt) 2015-09-22
BRPI0908569B1 BRPI0908569B1 (pt) 2020-02-11
BRPI0908569B8 true BRPI0908569B8 (pt) 2021-05-25

Family

ID=40533371

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908569A BRPI0908569B8 (pt) 2008-03-05 2009-02-27 estimuladores de secreção de insulina derivados de piridopirazinonas, seu uso, e composição farmacêutica

Country Status (18)

Country Link
US (3) US8178556B2 (pt)
EP (1) EP2247292B1 (pt)
JP (2) JP5735806B2 (pt)
KR (1) KR101589628B1 (pt)
CN (1) CN101951909B (pt)
AR (1) AR070796A1 (pt)
AU (1) AU2009221213B2 (pt)
BR (1) BRPI0908569B8 (pt)
CA (1) CA2718402C (pt)
DK (1) DK2247292T3 (pt)
EA (1) EA020372B1 (pt)
ES (1) ES2632964T3 (pt)
HU (1) HUE033849T2 (pt)
IL (1) IL207722A (pt)
MX (1) MX2010009577A (pt)
PT (1) PT2247292T (pt)
WO (1) WO2009109341A1 (pt)
ZA (1) ZA201007061B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
GB9413975D0 (en) * 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
JPH05155884A (ja) 1991-12-10 1993-06-22 Kyowa Hakko Kogyo Co Ltd 縮合ピラジン誘導体
GB9526558D0 (en) * 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives
SE9800836D0 (sv) * 1998-03-13 1998-03-13 Astra Ab New Compounds
DE19816983A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Bicyclen, deren Herstellung und deren Verwendung als Arzneimittel
US6200976B1 (en) * 1998-04-17 2001-03-13 Boehringer Ingelheim Pharma Kg Antithrombotic quinoxazolines
JP2000154139A (ja) * 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
WO2002076954A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
WO2005021547A2 (en) 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
PT1711184E (pt) * 2004-01-06 2007-09-24 Janssen Pharmaceutica Nv ''derivados de ( 3-oxo-3, 4-di-hidro-quinoxalin-2-il-amino)-benzamina e compostos relacionados como inibidores da fosforilase do glicogénio para o tratamento da diabetes e da obesidade''
WO2006126081A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2608672A1 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2007020521A1 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Pyridoyrazinones as pde-5 inhibitors
AU2007227664A1 (en) * 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2007109868A2 (en) * 2006-03-29 2007-10-04 Ivelin Terziev Fishing float
DK2013208T3 (da) * 2006-04-21 2011-08-15 Pfizer Prod Inc Pyridin[3,4-B]pyrazinoner
US7893066B2 (en) 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
BRPI0717502A2 (pt) * 2006-10-05 2015-06-16 Cv Therapeutics Inc Compostos heterocíclicos contendo nitrogênio bacíclico para uso como inibidores de estearoil-coa desaturase.
EP2433936A1 (en) * 2007-08-31 2012-03-28 Purdue Pharma LP Substituted-quinoxaline-type-piperidine compounds and the uses thereof

Also Published As

Publication number Publication date
US8609689B2 (en) 2013-12-17
US20130023537A1 (en) 2013-01-24
IL207722A (en) 2015-09-24
EP2247292B1 (en) 2017-04-12
EA020372B1 (ru) 2014-10-30
CA2718402A1 (en) 2009-09-11
EA201001405A1 (ru) 2011-04-29
HUE033849T2 (en) 2018-01-29
WO2009109341A1 (en) 2009-09-11
AR070796A1 (es) 2010-05-05
US20120122876A1 (en) 2012-05-17
PT2247292T (pt) 2017-07-17
ZA201007061B (en) 2011-06-29
CN101951909A (zh) 2011-01-19
DK2247292T3 (en) 2017-06-06
EP2247292A1 (en) 2010-11-10
JP6031079B2 (ja) 2016-11-24
CA2718402C (en) 2017-08-22
AU2009221213A1 (en) 2009-09-11
JP2015034184A (ja) 2015-02-19
US8642617B2 (en) 2014-02-04
JP2011514896A (ja) 2011-05-12
AU2009221213B2 (en) 2014-02-27
CN101951909B (zh) 2013-05-15
KR20100124803A (ko) 2010-11-29
BRPI0908569A2 (pt) 2015-09-22
JP5735806B2 (ja) 2015-06-17
MX2010009577A (es) 2010-09-24
US20110009417A1 (en) 2011-01-13
BRPI0908569B1 (pt) 2020-02-11
IL207722A0 (en) 2010-12-30
KR101589628B1 (ko) 2016-01-28
US8178556B2 (en) 2012-05-15
ES2632964T3 (es) 2017-09-18

Similar Documents

Publication Publication Date Title
BRPI0908406B8 (pt) Derivados de quinoxalinona, processo para a preparação dos mesmos, seu uso e composição farmacêutica
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
BRPI0922220A8 (pt) Uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
BR112015013809A2 (pt) derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BRPI0707302B8 (pt) compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende
UY31952A (es) 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
SV2009003236A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicas
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112012019437A2 (pt) 5-alquinil-pirimidinas
BR112014007193A2 (pt) derivados de pirazoloquinolinona, preparação dos mesmos e uso terapêutico dos mesmos
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
BRPI0908569B8 (pt) estimuladores de secreção de insulina derivados de piridopirazinonas, seu uso, e composição farmacêutica
BR112012009214A2 (pt) compostos
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
BRPI0915592A2 (pt) composto agonista do receptor de gpr119, processo para a preparação do composto, composição farmacêutica que o compreende, uso do mesmo e método para o tratamento ou profilaxia de diabetes mellitus do tipo ii
BR112012033402A2 (pt) moduladores de canais de íons conforme os compostos heterocíclicos fundidos
BR112012029395A2 (pt) lactamas piperdinil-substituídas como moduladores de gpr119
SV2011003855A (es) Heteroarilos sustituidos
BRPI0910832B8 (pt) derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos.
BRPI0907789A2 (pt) derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos
BR112014002958A2 (pt) "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso".
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
BR112014018767A8 (pt) Compostos de pirroldicarboxamidas fundidas e composição farmacêutica que os compreende

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/02/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF